PF-1355

Research use only, not for human use.

PF-1355 is a selective 2-thiouracil mechanism-based MPO inhibitor. PF-1355 is used for treatment of vasculitic diseases.

PF-1355 is a selective 2-thiouracil mechanism-based MPO inhibitor. PF-1355 is used for treatment of vasculitic diseases.(In Vitro):PF-1355 inhibits MPO activity in phorbol ester-stimulated human neutrophils as measured by taurine chlorination (EC50=1.47 μM) as well as lipopolysaccharide-treated human blood measuring residual MPO activity (EC50=2.03 μM) .(In Vivo):Oral administration of PF-1355 reduces plasma MPO activity, vascular edema, neutrophil recruitment, and elevates circulating cytokines. In a model of anti-glomerular basement membrane disease, albuminuria and chronic renal dysfunction are completely suppressed by PF-1355 treatment .

In a dose-responsive fashion, PF-1355 inhibits MPO activity in phorbol ester-stimulated human neutrophils as measured by taurine chlorination (EC50=1.47 μM) as well as lipopolysaccharide-treated human blood measuring residual MPO activity (EC50=2.03 μM).

Oral administration of PF-1355 reduces plasma MPO activity, vascular edema, neutrophil recruitment, and elevates circulating cytokines. In a model of anti-glomerular basement membrane disease, formerly known as Good pasture disease, albuminuria and chronic renal dysfunction are completely suppressed by PF-1355 treatment.

PF-06281355 | PF 06281355 | ZINC205721785

Others

Other Targets

Antifungal

——

——

1435467-38-1

321.35

C14H15N3O4S

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (155.59 mM)

O=C1C=C(C=2C=C(OC)C=CC2OC)N(C(=S)N1)CC(=O)N

——

(-20℃)

With Ice Pack

≥ 2 years